Autosomal dominant polycystic kidney disease represents the most common monogenic renal disorder, predisposing patients to progressive kidney failure and significant cardiovascular complications. Among these systemic features, the occurrence of unruptured intracranial aneurysms in ADPKD poses a devastating risk of aneurysmal rupture and subarachnoid hemorrhage. While clinicians widely recognize this cerebrovascular association, universal neurovascular screening remains controversial across international guidelines. A landmark systematic review and meta-analysis led by Brandon A. Nguyen and colleagues evaluated 24 observational studies encompassing 5,907 asymptomatic patients. The study provides essential quantitative insights to refine clinical risk stratification and establish clear screening indications. By defining high-risk patient subgroups, these robust findings guide clinicians in identifying which asymptomatic individuals derive the greatest benefit from early magnetic resonance angiography.

Prevalence and Vascular Vulnerability: Intracranial Aneurysms in ADPKD

The systematic review demonstrated an overall intracranial aneurysm prevalence of 12.6% among screened asymptomatic patients with autosomal dominant polycystic kidney disease. This proportion is nearly five times higher than the 2% to 3% prevalence documented in the general population. In addition, patients with polycystic kidney disease tend to develop intracranial lesions at significantly younger ages. Consequently, these individuals face an elevated cumulative lifetime hazard of aneurysm formation, expansion, and sudden rupture. Subarachnoid hemorrhage resulting from aneurysmal rupture carries catastrophic consequences, leading to high morbidity and substantial short-term mortality. Although earlier clinical protocols prioritized screening exclusively for patients with a documented family history of cerebrovascular events, contemporary observational data demonstrate that occult aneurysms also arise frequently in patients without familial history. Therefore, relying solely on classical family history may fail to identify many vulnerable individuals before life-threatening hemorrhage occurs. Establishing targeted screening protocols remains vital for early intervention.

Key Clinical Predictors Identified in the Meta-Analysis

The quantitative meta-analysis delineated several distinct clinical variables that significantly increase the odds of detecting an unruptured intracranial aneurysm. First, female sex emerged as an independent predictor, conferring a 63% higher likelihood of aneurysm detection with zero heterogeneity across 18 studies. Second, a positive family history of either intracranial aneurysm or subarachnoid hemorrhage more than doubled detection odds. When isolating a specific family history of subarachnoid hemorrhage, the odds increased nearly threefold. Third, patients with moderate-to-severe renal dysfunction—defined as chronic kidney disease stage 3 or greater—exhibited marked vulnerability, with more than two-and-a-half times higher odds of harboring an aneurysm. Fourth, systemic hypertension independently increased aneurysm detection rates. Interestingly, variables such as age older than 45 years, a generic family history of renal cysts, active smoking status, and hepatic cysts did not achieve statistical significance in the pooled analysis. Thus, clinicians should prioritize screening for female patients, individuals with advanced renal impairment, hypertensive patients, and those with confirmed familial cerebrovascular events.

Pathophysiological Mechanisms Linking Renal Disease and Cerebrovascular Risk

The biological link underlying vascular wall weakness in polycystic kidney disease centers on pathogenic mutations in the PKD1 and PKD2 genes. These genes encode polycystin-1 and polycystin-2, respectively, which form vital mechanosensory receptor complexes in vascular endothelial cells and smooth muscle layers. Consequently, disrupted polycystin function impairs intracellular calcium signaling, alters extracellular matrix remodeling, and reduces arterial elasticity. This intrinsic structural frailty predisposes the internal elastic lamina of cerebral vessels to focal degeneration and saccular outpouching. Furthermore, progressive chronic kidney disease accelerates vascular deterioration through chronic low-grade inflammation, oxidative stress, and endothelial dysfunction. In addition, systemic activation of the renin-angiotensin-aldosterone axis drives persistent hypertension, imposing elevated hemodynamic shear stress at cerebral arterial bifurcations. As glomerular filtration rate drops into stage 3 or worse, arterial stiffness and vascular remodeling intensify substantially. Therefore, intrinsic genetic vessel wall weakness and progressive hemodynamic stress act synergistically to drive cerebrovascular aneurysm formation.

Diagnostic Modalities and Screening Protocols in Clinical Practice

Effective and safe detection of occult intracranial aneurysms requires imaging modalities that avoid nephrotoxicity, especially in individuals with compromised renal reserve. Magnetic resonance angiography without gadolinium contrast—specifically three-dimensional time-of-flight imaging—serves as the primary screening modality of choice. Time-of-flight sequences deliver excellent spatial resolution of the circle of Willis without exposing patients to the risks of nephrogenic systemic fibrosis or iodinated contrast-induced nephropathy. Alternatively, high-resolution computed tomography angiography provides a dependable substitute when magnetic resonance imaging is contraindicated, although clinicians must carefully consider radiation and contrast exposure. When baseline neuroimaging results are normal in high-risk patients, current consensus guidelines suggest repeating screening at intervals of five to ten years. Conversely, when an asymptomatic aneurysm is detected, clinicians should schedule follow-up vascular imaging within six to twelve months to assess dimensional stability and anatomical morphology.

Practical Strategies for Medical and Interventional Management

Managing unruptured intracranial aneurysms in polycystic kidney disease requires a multidisciplinary strategy integrating tight hemodynamics and neurointerventional expertise. Rigorous blood pressure control forms the foundation of non-operative management. Physicians generally target systolic levels below 120 to 130 mmHg using renin-angiotensin-aldosterone system inhibitors. Furthermore, lifestyle optimization is essential, requiring complete smoking cessation, moderation of alcohol use, and avoidance of heavy isometric exertion. For stable aneurysms measuring under seven millimeters in low-risk vascular territories, longitudinal surveillance with non-contrast magnetic resonance angiography is standard. However, if an aneurysm expands during follow-up, exceeds seven millimeters, presents irregular morphology, or involves posterior circulation arteries, prompt preventative intervention is indicated. Endovascular coiling, with or without flow diversion or stent assistance, represents the preferred therapeutic approach due to lower procedural morbidity compared to open microsurgical clipping. Neurovascular specialists must personalize intervention plans according to aneurysm geometry, patient age, and operative risk.

Evolving Guidelines and Future Directions in Risk Stratification

Updated international guidelines, including recent KDIGO clinical practice recommendations, emphasize risk-stratified decision-making rather than indiscriminate universal screening. While historical guidelines restricted neuroimaging to individuals with an explicit familial history of aneurysm or hemorrhage, meta-analytic evidence supports expanding targeted screening criteria. Specifically, clinicians should offer screening to female patients with advanced chronic kidney disease, poorly controlled hypertension, or high-risk occupations where sudden impairment poses severe danger. Moreover, ongoing research is exploring how distinct PKD1 and PKD2 allelic variants influence vascular phenotypes, which could soon enable personalized genomic risk scores. In addition, computational fluid dynamics and wall shear stress modeling hold promise for identifying high-risk aneurysms prone to sudden enlargement. Until automated risk models enter routine practice, clinicians must engage every patient with polycystic kidney disease in structured shared decision-making to balance screening benefits against procedural and psychological risks.

Why are patients with ADPKD at higher risk for intracranial aneurysms?

Mutations in the PKD1 and PKD2 genes disrupt polycystin proteins within vascular endothelial and smooth muscle cells. This defect weakens arterial wall structural integrity and alters extracellular matrix remodeling. When compounded by chronic hypertension and hemodynamic shear stress, weakened cerebral vessels progressively dilate into saccular aneurysms.

Which screening method is preferred for detecting intracranial aneurysms in ADPKD?

Time-of-flight magnetic resonance angiography without intravenous contrast is the first-line screening modality. It provides high-resolution visualization of cerebral vasculature without exposing vulnerable kidneys to nephrotoxic iodinated agents or gadolinium-associated complications. Non-contrast imaging offers an accurate, safe, and reproducible method for longitudinal surveillance.

How often should asymptomatic ADPKD patients undergo repeat aneurysm screening?

High-risk patients with an initial negative screening scan generally undergo repeat magnetic resonance angiography every five to ten years. However, if an unruptured aneurysm is identified and managed conservatively, clinicians typically perform follow-up imaging within six to twelve months to confirm dimensional and morphological stability.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Nguyen BA et al. Risk factors for unruptured intracranial aneurysms in asymptomatic patients with autosomal dominant polycystic kidney disease: who needs screening? A systematic review and meta-analysis. J Neurosurg. 2025 Jul 01. doi: 10.3171/2024.9.JNS241175. PMID: 39951701.
2. Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Care of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(1S):S1-S120.
3. Giet O, Pirson Y, Demoulin N. Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019;14(8):1242-1244.
4. Rozenfeld MN, Ansari SA, Mohan P, Shaibani A, Russell EJ, Hurley MC. Autosomal dominant polycystic kidney disease and intracranial aneurysms: is follow-up screening justified? Neuroimaging Clin N Am. 2021;31(2):167-177.